CClinicalTrials.gg
CompletedNCT07467291Updated Oct 2, 2026

SPSIP Block vs SAP Block for Post-VATS Pain

An observational study in Postoperative Pain and Video-Assisted Thoracoscopic Surgery, sponsored by Firat University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Firat University · Observational

Updated Oct 2, 2026Start date movedEligibility revised+1 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Comparison of Superior Serratus Posterior Intercostal Plane Block and Serratus Anterior Plane Block for Pain Management Following Video-Assisted Thoracoscopic Surgery: A Prospective Observational Cohort Study

Introduction Video-assisted thoracoscopic surgery (VATS) is associated with lower postoperative pain, shorter hospital stays, and better preservation of pulmonary function compared with conventional thoracotomy, owing to its minimally invasive nature. Although VATS was initially performed using a multi-port technique, it has evolved into a single-port approach, reflecting advances in surgical techniques and equipment. In Uniportal VATS, limiting surgical trauma to a single intercostal space may reduce the risk of chronic postoperative pain by decreasing intercostal nerve damage.

Because inadequate pain control after VATS may predispose patients to developing chronic post-thoracotomy pain syndrome (PTPS), effective postoperative analgesia is critically important. Therefore, regional analgesic techniques are recommended as part of multimodal analgesia. PROSPECT guidelines do not recommend the routine use of thoracic epidural analgesia for VATS, despite its effectiveness, because of its invasiveness; instead, they emphasize peripheral blocks such as paravertebral block and erector spinae plane block.

Although not included among first-line analgesic interventions in PROSPECT guidelines, the serratus anterior plane block (SAPB) is a widely used and well-established technique in thoracic surgery. In addition, the superior serratus posterior intercostal plane block (SPSIPB) is gaining attention in VATS surgery because of its analgesic effect covering the C3-T10 dermatomes.

Although there are studies in the literature comparing SAPB with different regional techniques, direct comparisons with SPSIPB are limited. Therefore, this prospective observational cohort study aimed to compare postoperative analgesic outcomes in patients undergoing uniportal VATS who received either ultrasound-guided SPSIPB or SAPB, with the block type selected by the attending anesthesiologist as part of routine clinical care.

Read the detailed description

This single-center prospective observational cohort study included adult patients undergoing elective uniportal VATS who received an ultrasound-guided serratus anterior plane block (SAPB) or serratus posterior superior intercostal plane block (SPSIPB) for postoperative analgesia. Patients were not randomized; the block type was selected by the attending anesthesiologist as part of routine clinical care. All blocks were performed with 30 mL of 0.25% bupivacaine at the end of surgery. Postoperative pain scores and rescue analgesic use were recorded in routine observation forms by recovery unit and ward nurses who were not informed of the block type. Postoperative analgesia followed a standard multimodal protocol, with 50 mg intravenous tramadol given as rescue analgesia when the resting NRS score was 4 or higher.

02

Conditions studied

  • Postoperative Pain
  • Video-Assisted Thoracoscopic Surgery

Browse trials for

Keywords

  • VATS
  • Serrratus Posterior Superior İnterfascial Plane Block
  • Serratus Anterior Plane Block
  • Postoperative Analgesia
  • Numeric Rating Scale
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 80 is below the median of 102 across 608 observational studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Firat University is the lead sponsor of 112 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients undergoing elective uniportal video-assisted thoracoscopic surgery at Firat University Hospital who received either a serratus anterior plane block or a serratus posterior superior intercostal plane block for postoperative analgesia as part of routine care.

Inclusion criteria

  • aged 18-65 years,
  • with American Society of Anesthesiologists (ASA) physical status classification I-III,
  • Body Mass Index (BMI) \< 35 kg/m²,
  • and who read and signed the informed consent form were included.

Exclusion criteria

Exclusion Criteria:

  • inability to communicate in Turkish, refusal to consent,
  • inability to use the numerical pain rating scale (NRS),
  • allergy to local anesthetics or study-specific analgesics;
  • pregnancy or breastfeeding;
  • uncontrolled anxiety or substance dependence;
  • history of thoracic surgery,
  • trauma,
  • neuromuscular or peripheral nerve disorders;
  • diabetes mellitus,
  • hepatic or renal insufficiency,
  • coagulation disorders;
  • chronic opioid or steroid use;
  • widespread pain;
  • anticoagulant therapy;
  • infection at the block application site;
  • early termination of surgery;
  • absence of planned postoperative extubation.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • Serratus posterior superior intercostal plane block Group

    Patients who received an ultrasound-guided serratus posterior superior intercostal plane block (30 mL of 0.25% bupivacaine) at the end of uniportal VATS for postoperative analgesia. The block type was selected by the attending anesthesiologist as part of routine clinical care; patients were not randomized.

    Procedure: Serratus posterior superior intercostal plane block

  • Serratus Anterior Plane Block (SAPB) group

    Patients who received an ultrasound-guided serratus anterior plane block (30 mL of 0.25% bupivacaine) at the end of uniportal VATS for postoperative analgesia. The block type was selected by the attending anesthesiologist as part of routine clinical care; patients were not randomized.

    Procedure: Serratus Anterior Plane Block (SAPB) group

Interventions

  • ProcedureSerratus Anterior Plane Block (SAPB) group

    The block was performed with the patient in the lateral decubitus position. Ultrasound-guided SAPB was performed by the same anesthesiologist with over three years of experience in ultrasound-guided regional anesthesia, using a high-frequency linear probe (LOGIQ e Ultrasound, GE HealthCare, United States). The probe was positioned parallel to the mid-axillary line, and the ribs were readily identified as hyperechogenic lines. The fifth rib was identified in the mid-axillary line. Using an in-plane technique, the needle was placed in the myofascial plane between the serratus anterior muscle and the fifth rib, and 30 mL of 0.25% bupivacaine was injected.

  • ProcedureSerratus posterior superior intercostal plane block

    The procedure was performed with the patient in the lateral decubitus position. After a slight lateral displacement of the scapula, the scapular spine was visualized with ultrasound, and the probe was moved medially. After locating the tip of the scapular spine, the probe was placed sagittally at the superior angle of the scapula, and the third rib was visualized. The block needle was advanced craniocaudally and placed between the posterior superior serratus muscle and the third rib. Hydrodissection was performed with an injection of 2 mL of saline to confirm block needle placement. After confirming the block site, 30 mL of 0.25% bupivacaine was injected.

06

What researchers measure

Primary outcomes

  1. To determine the effectiveness of ultrasound-guided SPSIP block versus SAP block after VATS using postoperative NRS pain scores.

    The NRS score is based on the patient rating their pain on a scale from 0 to 10. Zero indicates no pain, while 10 indicates the most severe pain possible.

    Time frame: NRS scores will be assessed upon admission to the post-anesthesia care unit (0 min), at 30 minutes, and at 1, 6, 12, 18, and 24 hours postoperatively.

Secondary outcomes

  1. QoR-15 recovery score

    The QoR-15 (Quality of Recovery-15) scale is a patient-reported outcome questionnaire used to evaluate the quality of postoperative recovery. The QoR-15 consists of 15 items assessing five domains: pain, physical comfort, physical independence, psychological support, and emotional state. The total score ranges from 0 to 150, with higher scores indicating a better quality of recovery.

    Time frame: up to 48 hours

  2. Time to first rescue analgesia

    The time to first rescue analgesia, defined as the time interval between recovery from anesthesia and the first administration of rescue analgesia (50 mg intravenous tramadol for NRS ≥4), was recorded and expressed in hours.

    Time frame: up to 24 hours

  3. The total amount of rescue analgesic consumption

    The total amount of rescue analgesic consumption within the first 24 postoperative hours (mg) was also documented.

    Time frame: up to 24 hours

  4. The incidence of block-related complications.

    block-related complications such as hematoma, paralysis, hypotension or other adverse events were recorded.

    Time frame: up to 48 hours

07

Study locations

1 site
  • Fırat University Faculty of Medicine Hospital
    Elâzığ, 23100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Start date
Jan 20, 2026→Mar 13, 2026
Oct 2, 2026
Also revised
eligibility and design
Show all 1 update
  1. Oct 2, 2026
    Start date Jan 20, 2026→Mar 13, 2026
    Eligibility Criteria revised
    Design Study type changed
    + 6 other changes: index terms, verification date, description, conditions, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07467291
Lead sponsor
Firat University
Responsible party
AHMET AKSU (Assistant Professor, Firat University) — Principal investigator
First posted
Mar 12, 2026
Start date
Mar 13, 2026
Primary completion
Aug 1, 2026
Completion
Aug 1, 2026
Last update
Oct 2, 2026

Study contacts

Ahmet Aksu, MD
principal investigator · Firat University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion